These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

650 related articles for article (PubMed ID: 16101169)

  • 21. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an exploratory analysis of a Gynecologic Oncology Group study.
    Chan JK; Tian C; Fleming GF; Monk BJ; Herzog TJ; Kapp DS; Bell J
    Gynecol Oncol; 2010 Mar; 116(3):301-6. PubMed ID: 19945740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease.
    Ho CM; Huang YJ; Chen TC; Huang SH; Liu FS; Chang Chien CC; Yu MH; Mao TL; Wang TY; Hsieh CY
    Gynecol Oncol; 2004 Jul; 94(1):197-203. PubMed ID: 15262142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
    Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
    Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.
    Vapattanawong P
    J Med Assoc Thai; 2006 Sep; 89(9):1357-61. PubMed ID: 17100369
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose cisplatin carboplatin chemotherapy in primary advanced epithelial ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1993 Nov; 51(2):182-6. PubMed ID: 8276291
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
    Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
    Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Timing isn't everything: an analysis of when to start salvage chemotherapy in ovarian cancer.
    McMeekin DS; Tillmanns T; Chaudry T; Gold M; Johnson G; Walker J; Mannel R
    Gynecol Oncol; 2004 Oct; 95(1):157-64. PubMed ID: 15385126
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study.
    Pignata S; Breda E; Scambia G; Pisano C; Zagonel V; Lorusso D; Greggi S; De Vivo R; Ferrandina G; Gallo C; Perrone F
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):229-36. PubMed ID: 18243011
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
    Pfisterer J; Weber B; Reuss A; Kimmig R; du Bois A; Wagner U; Bourgeois H; Meier W; Costa S; Blohmer JU; Lortholary A; Olbricht S; Stähle A; Jackisch C; Hardy-Bessard AC; Möbus V; Quaas J; Richter B; Schröder W; Geay JF; Lück HJ; Kuhn W; Meden H; Nitz U; Pujade-Lauraine E; ;
    J Natl Cancer Inst; 2006 Aug; 98(15):1036-45. PubMed ID: 16882940
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.
    Akeson M; Zetterqvist BM; Dahllöf K; Brännström M; Horvath G
    Acta Obstet Gynecol Scand; 2008; 87(12):1343-52. PubMed ID: 18951208
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
    Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
    Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 protocol 1.
    Pecorelli S; Favalli G; Gadducci A; Katsaros D; Panici PB; Carpi A; Scambia G; Ballardini M; Nanni O; Conte P;
    J Clin Oncol; 2009 Oct; 27(28):4642-8. PubMed ID: 19704064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between time interval from primary surgery to the start of taxane- plus platinum-based chemotherapy and clinical outcome of patients with advanced epithelial ovarian cancer: results of a multicenter retrospective Italian study.
    Gadducci A; Sartori E; Landoni F; Zola P; Maggino T; Maggioni A; Cosio S; Frassi E; LaPresa MT; Fuso L; Cristofani R
    J Clin Oncol; 2005 Feb; 23(4):751-8. PubMed ID: 15613698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
    Goldberg JM; Piver MS; Hempling RE; Recio FO
    Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.
    Pignata S; Ferrandina G; Scarfone G; Scollo P; Odicino F; Cormio G; Katsaros D; Frigerio L; Mereu L; Ghezzi F; Manzione L; Lauria R; Breda E; Alletti DG; Ballardini M; Vernaglia A; Sorio R; Tumolo S; Musso P; Magni G; Pisano C; Morabito A
    Crit Rev Oncol Hematol; 2009 Sep; 71(3):233-41. PubMed ID: 19179095
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Analysis of treatment and prognosis of recurrent epithelial ovarian carcinoma].
    Yuan GW; Wu LY; Yao HW; Hou JL; Li XG; Liu LY
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):710-3. PubMed ID: 20021871
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparison of therapeutic efficacy between TP regimen and CBP regimen on epithelial ovarian cancer after optimal cytoreductive operation].
    Gao KF; Liu FY; Chen FJ; Feng YL
    Ai Zheng; 2007 Apr; 26(4):431-4. PubMed ID: 17430668
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
    Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
    BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Predictive value of P53 expression in selecting first-line chemotherapy regimen for advanced epithelial ovarian carcinoma].
    Zhao XD; Zhang Y; He SR; Yang L
    Ai Zheng; 2005 Dec; 24(12):1542-5. PubMed ID: 16351810
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of relapsed carcinoma of the ovary with single-agent paclitaxel following exposure to paclitaxel and platinum employed as initial therapy.
    Zanotti KM; Belinson JL; Kennedy AW; Webster KD; Markman M
    Gynecol Oncol; 2000 Nov; 79(2):211-5. PubMed ID: 11063646
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.